Genedata and Axxam Announce High Throughput Screening Data Analysis Collaboration

Genedata, the leading provider of in silico solutions for the pharmaceutical and life science industries, and Axxam, a leading biotechnology research organization offering early-stage discovery research services for the life science industry, have signed a multi-year contract for the implementation of the Genedata Screener®data analysis and management platform into Axxam’s high throughput screening process.
With an increasing number of pharma and life science companies outsourcing entire stages of their research cycle, the contributions of contract research organizations (CROs) to drug development have never been more crucial. Faster development, earlier decisions on project failures, and higher approval success rates are becoming the norm. To continuously meet those high standards, Axxam relies on Genedata Screener. Screener’s high-quality, high-performance modular system rapidly and flexibly analyzes, integrates and manages all assay data and then combines it with chemical, pharmacological and in vivo information to support Axxam scientists in prioritizing compounds and identifying quality lead structures with the highest confidence. Screener’s open and scalable architecture integrates with existing infrastructures, which allows it to be tailored to specific discovery processes, maximizing value.